Surface modified poly(amido) amine dendrimers as diverse nanomolecules for biomedical applications

Expert Opinion on Drug Delivery

Volumn 6, Issue 8, 2009, Pages 835-850

  Yellepeddi, Venkata K ^a   Kumar, Ajay ^a   Palakurthi, Srinath ^a  

^a TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

Cytotoxicity; Drug delivery; Drug targeting; Gene transfection; PAMAM dendrimers; PD; PK; Surface modification

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); ANTISENSE OLIGODEOXYNUCLEOTIDE; ARGININE; ARGINYLGLYCYLASPARTIC ACID; BH3 PROTEIN; BIOTIN; BLEOMYCIN; CETUXIMAB; CHOLESTEROL; CISPLATIN; CYANOVIRIN N; DENDRIMER; DOXORUBICIN; ESTROGEN; FOLIC ACID; GADOLINIUM; GONADORELIN; HORSERADISH PEROXIDASE; INDOMETACIN; MACROGOL 3350; MANNOSE; METHOTREXATE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 425; MONOCLONAL ANTIBODY J591; POLYAMIDOAMINE; PORPHYRIN; TRANSACTIVATOR PROTEIN; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABSORPTION; BIOCOMPATIBILITY; BIODEGRADABILITY; CELL MEMBRANE; CELL MEMBRANE PERMEABILITY; CELL TRANSPORT; CHEMICAL MODIFICATION; CHEMICAL STRUCTURE; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG TARGETING; GENE DELIVERY SYSTEM; GENETIC TRANSFECTION; HUMAN; IN VIVO STUDY; MACROMOLECULE; MOLECULAR RECOGNITION; NANOMEDICINE; NONHUMAN; PHARMACODYNAMICS; PHOTODYNAMICS; RETICULOENDOTHELIAL SYSTEM; REVIEW; SIGNAL TRANSDUCTION; SURFACE PROPERTY; TARGET CELL;

ADMINISTRATION, ORAL; CELL MEMBRANE PERMEABILITY; DENDRIMERS; DRUG DESIGN; GENE TRANSFER TECHNIQUES; HUMANS; NANOSTRUCTURES; PHARMACEUTICAL PREPARATIONS; POLYAMINES; SURFACE PROPERTIES;

EID: 68149126383     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425240903061251     Document Type: Review

References (112)

1. Newkome GR, Yao ZQ, Baker GR, Gupta VK. Micells. Part 1. Cascade molecules: a new approach to micelles A[27]-Arborol. J Org Chem 1985;50:2003-2004
2. Tomalia DA, Baker H, Dewald J, et al. A new class of polymers: starburst-dendritic macromolecules. Polymer J 1985;17:117-132
3. Wängler C, Moldenhauer G, Saffrich R, et al. PAMAM structure-based multifunctional fluorescent conjugates for improved fluorescent labelling of biomacromolecules. Chemistry 2008;14:8116-8130
4. Parimi S, Barnes TJ, Prestidge CA. PAMAM dendrimers interactions with supported lipid bilayers: a kinetic and mechanistic investigation. Langmuir 2008;24(23):13532-13539
5. El-sayed M, Kiani MF, Naimark MD, et al. Extravasation of poly(amidoamine) (PAMAM) dendrimers across microvascular network endothelium. Pharm Res 2001;18:23-28
6. Majoros IJ, Myc A, Thomas T, et al. PAMAM dendrimer-based multifunctional conjugate for cancer therapy: synthesis, characterization, and functionality. Biomacromolecules 2006;7:572-579 (Pubitemid 43309153)
7. Konda SD, Aref M, Wang S, et al. Specific targeting of folate-dendrimer MRI contrast agents to the high affinity folate receptor expressed in ovarian tumor xenografts. MAGMA 2001;12:104-113 (Pubitemid 32510128)
8. Shukla S, Wu G, Chatterjee M, et al. Synthesis and biological evaluation of folate receptor-targeted boronated PAMAM dendrimers as potential agents for neutron capture therapy. Bioconjug Chem 2003;14:158-216 (Pubitemid 36169029)
9. Chandrasekar D, Sistla R, Ahmad FJ, et al. Folate coupled poly(ethyleneglycol) conjugates of anionic poly(amidoamine) dendrimer for inflammatory tissue specific drug delivery. J Biomed Mater Res A 2007;82:92-103 (Pubitemid 46906494)
10. Kukowska-Latallo JF, Candido KA, Cao Z, et al. Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res 2005;65:5317-5324 (Pubitemid 40827344)
11. Yang W, Cheng Y, Xu T, et al. Targeting cancer cells with biotin-dendrimer conjugates. Eur J Med Chem 2008 (In Press)
12. Xu H, Regino CA, Koyama Y, et al. Preparation and preliminary evaluation of a biotin-targeted, lectin-targeted dendrimer-based probe for dual-modality magnetic resonance and fluorescence imaging. Bioconjug Chem 2007;18:1474-1482 (Pubitemid 47464054)
13. Mangold SL, Morgan JR, Strohmeyer GC, et al. Cyanovirin-N binding to Manalpha1-2Man functionalized dendrimers. Org Biomol Chem 2005;3:2354-2358
14. Mangold SL, Cloninger MJ. Binding of monomeric and dimeric Concanavalin A to mannose-functionalized dendrimers. Org Biomol Chem 2006;4:2458-2465
15. Dougherty TJ, Gomer CJ, Henderson BW, et al. Photodynamic therapy. J Natl Cancer Inst 1998;90:889-905
16. Ndoye A, Merlin JL, Leroux A, et al. Enhanced gene transfer and cell death following P53 gene transfer using photochemical internalisation internalisation of glucosylated PEI-DNA complexes. J Gene Med 2004;6:884-894 (Pubitemid 40228104)
17. Berg K, Dietze A, Kaalhus O, Hogset A. Site-specific drug delivery by photochemical internalization enhances the antitumor effect of bleomycin. Clin Cancer Res 2005;11:8476-8485 (Pubitemid 41746963)
18. Folini M, Berg K, Millo E, et al. Photochemical internalization of a peptide nucleic acid targeting the catalytic subunit of human telomerase. Cancer Res 2003;63:3490-3494 (Pubitemid 36798078)
19. Lai PS, Lou PJ, Peng CL, et al. Doxorubicin delivery by polyamidoamine dendrimer conjugation and photochemical internalization for cancer therapy. J Control Release 2007;122:39-46
20. Shieh MJ, Peng CL, Lou PJ, et al. Non-toxic phototriggered gene transfection by PAMAM-porphyrin conjugates. J Control Release 2008;129:200-206
21. Margerum LD, Campion BK, Koo M, et al. Gadolinium(III) DO3A macrocycles and polyethylene glycol coupled to dendrimers: effect of molecular weight on physical and biological properties of macromolecular magnetic resonance imaging contrast agents. J Alloy Compd 1997;249:185-190 (Pubitemid 127415072)
22. Jendrusch-Borkowski B, Awad J, Wasgestian F. Reactions of chromium (III)- and cobalt(III)-amine-complexes with starburst (PAMAM) dendrimers. J Inclusion Phenomena Macrolytic Chem 1999;35:355-359
23. Benini PGZ, McGarvey BR, Franco DW. Fictionalization of PAMAM dendrimers with [RuIII(edta)(H2O)]. Nitric Oxide 2008;19:245-251
24. Malik N, Evagorou EG, Duncan R. Dendrimer-platinate: a novel approach to cancer chemotherapy. Anticancer Drugs 1999;10:767-776 (Pubitemid 30015678)
25. Shukla R, Thomas TP, Desai AM, et al. HER2 specific delivery of methotrexate by dendrimer conjugated anti-HER2 mAb. Nanotechnology 2008;19:295102 (Pubitemid 351991642)
26. Patri AK, Myc A, Beals J, et al. Synthesis and in vitro testing of J591 antibody-dendrimer conjugates for targeted prostate cancer therapy. Bioconjug Chem 2004;15:1174-1181 (Pubitemid 39552005)
27. Kobayashi H, Sato N, Saga T, et al. Monoclonal antibody-dendrimer conjugates enable radiolabeling of antibody with markedly high specific activity with minimal loss of immunoreactivity. Eur J Nucl Med 2000;27:1334-1339 (Pubitemid 30680622)
28. Wängler C, Moldenhauer G, Eisenhut M, et al. Antibody-dendrimer conjugates: the number, not the size of the dendrimers, determines the immunoreactivity. Bioconjug Chem 2008;19:813-820 (Pubitemid 351614537)
29. Boswell CA, Eck PK, Regino CA, et al. Synthesis, characterization, and biological evaluation of integrin alphavbeta3-targeted PAMAM dendrimers. Mol Pharm 2008;5:527-539
30. Yang H, Kao WJ. Synthesis and characterization of nanoscale dendritic RGD clusters for potential applications in tissue engineering and drug delivery. Int J Nanomed 2007;2(1):89-99 (Pubitemid 46901785)
31. Shukla R, Thomas TP, Peters J, et al. Tumor angiogenic vasculature targeting with PAMAM dendrimers-RGD conjugates. Chem Commun (Camb) 2005;5739-5741 (Pubitemid 43028741)
32. Myc A, Patri AK, Baker JR Jr. Dendrimer-based BH3 conjugate that targets human carcinoma cells. Biomacromolecules 2007;8:2986-2989 (Pubitemid 350011615)
33. Thomas TP, Shukla R, Kotlyar A, et al. Dendrimer#Epidermal growth factor conjugate displays superagonist activity. Biomacromolecules 2008;9(2):603-609 (Pubitemid 351298484)
34. Wu G, Barth RF, Yang W, et al. Targeted delivery of methotrexate to epidermal growth factor receptor-positive brain tumors by means of cetuximab (IMC-C225) dendrimers bioconjugates. Mol Cancer Ther 2006;5(1):52-59
35. Zeng YL, Huang HW, Jiang JH, et al. Novel looped enzyme-polyamidoamine dendrimer nanohybrids used as biosensor matrix. Anal Chim Acta 2007;604:170-176
36. Xiangyang S, Baker JR Jr. Synthesis, characterization and stability of a luteinizing hormone-releasing hormone (LHRH)-functionalized poly(amidoamine) dendrimer conjugate. J Biomater Sci Polym Ed 2008;19:131-142
37. Liu H, Guo J, Jin L, et al. Fabrication and functionalization of dendritic poly(amidoamine)-immobilized magnetic polymer composite microspheres. J Phys Chem B 2008;112:3315-3321
38. Oliveira JM, Kotobuki N, Marques AP, et al. Surface engineered carboxymethylchitosan/poly(amidoamine) dendrimer nanoparticles for intracellular targeting. Adv Funct Mater 2008;18:1840-1853
39. Zhang XQ, Intra J, Salem AK. Conjugation of polyamidoamine dendrimers on biodegradable microparticles for nonviral gene delivery. Bioconjug Chem 2007;18:2068-2076 (Pubitemid 350220010)
40. Papagiannaros A, Dimas K, Papaioannou GT, Demetzos C. Doxorubicin-PAMAM dendrimer complex attached to liposomes: cytotoxic studies against human cancer cell lines. Int J Pharm 2005;302:29-38 (Pubitemid 41242749)
41. Mareck U, Geyer H, Guddat S, et al. Identification of the aromatase inhibitors anastrozole and exemestane in human urine using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2006;20:1954-1962 (Pubitemid 43893351)
42. Sarkar K, Yang H. Encapsulation and extended release of anti-cancer anastrozole by stealth nanoparticles. Drug Deliv 2008;15:343-346
43. Pan G, Lemmouchi Y, Akala EO, Bakare O. Studies on PEGylated and drug- loaded PAMAM dendrimers. J Bioactive Compatible Polymers 2005;20:113-128 (Pubitemid 40144216)
44. Yang H, Lopina ST. In Vitro enzymatic stability of dendritic peptides. J Biomed Mater Res A 2006;76A(2):398-407
45. Guillaudeu SJ, Fox ME, Haidar YM, et al. PEGylated dendrimers with core functionality for biological applications. Bioconjugate Chem 2008;19:461-469
46. El-Sayed M, Ginski M, Rhodes C, Ghandeharia H. Transepithelial transport of poly(amidoamine) dendrimers across Caco-2 cell monolayers. J Controlled Release 2002;81:355-365 (Pubitemid 34607155)
47. El-Sayed M, Rhodes CA, Ginski M, Ghandehari H. Transport mechanism(s) of poly (amidoamine) dendrimers across Caco-2 cell monolayers. Int J Pharm 2003;265:151-157 (Pubitemid 37176956)
48. Kitchens KM, Kolhatkar RB, Swaan PW, et al. Transport of poly(Amidoamine) dendrimers across Caco-2 cell monolayers: influence of size, charge and fluorescent labeling. Pharm Res 2006;23:2818-2826
49. Kitchens KM, Foraker AB, Kolhatkar RB, et al. Endocytosis and interaction of poly (Amidoamine) dendrimers with Caco-2 cells. Pharm Res 2007;24:2138-2145
50. Seiler N, Delcros JG, Moulinoux JP. Polyamine transport in mammalian cells: an update. Int J Biochem Cell Biol 1996;28:843-861 (Pubitemid 26284212)
51. Pisal DS, Yellepeddi VK, Kumar A, et al. Permeability of surface-modified polyamidoamine (PAMAM) dendrimers across Caco-2 cell monolayers. Int J Pharm 2008;350:113-121
52. Pisal DS, Yellepeddi VK, Kumar A, Palakurthi S. Transport of surface engineered polyamidoamine (PAMAM) dendrimers across IPEC-J2 cell monolayers. Drug Deliv 2008;15:515-522
53. Duncan R, Izzo L. Dendrimer biocompatibility and toxicity. Adv Drug Deliv Rev 2005;57:2215-2237
54. Brazeau GA, Attia S, Poxon S, Hughes JA. In vitro myotoxicity of selected cationic macromolecules used in non-viral gene delivery. Pharm Res 1998;15:680-684
55. Jevprasesphant R, Penny J, Attwood D, et al. Engineering of dendrimer surfaces to enhance transepithelial transport and reduce cytotoxicity. Pharm Res 2003;20:1543-1550 (Pubitemid 37268266)
56. Najlah M, Freeman S, Attwood D, D'Emanuele A. In vitro evaluation of dendrimer prodrugs for oral drug delivery. Int J Pharm 2007;336:183-190
57. Ke W, Zhao Y, Huang R, et al. Enhanced oral bioavailability of doxorubicin in a dendrimer drug delivery system. J Pharm Sci 2008;97:2208-2216
58. Kolhatkar RB, Swaan P, Ghandehari H. Potential oral delivery of 7-Ethyl-10-Hydroxy-camptothecin (SN-38) using poly(amidoamine) dendrimers. Pharm Res 2008;25:1723-1729
59. Najlah M, Freeman S, Attwood D, D'Emanuele A. Synthesis and assessment of first-generation polyamidoamine dendrimer prodrugs to enhance the cellular permeability of P-gp substrates. Bioconjugate Chem 2007;18:937-946 (Pubitemid 47010817)
60. Eliyahu H, Barenholz Y, Domb AJ. Polymers for DNA delivery. Molecules 2005;10:34-64
61. Kono K, Akiyama H, Takahashi T, et al. Transfection activity of polyamidoamine dendrimers having hydrophobic amino acid residues in the periphery. Bioconjug Chem 2005;16:208-214 (Pubitemid 40129695)
62. Futaki S. Arginine-rich peptides: potential for intracellular delivery of macromolecules and the mystery of the translocation mechanisms. Int J Pharm 2002;245:1-7 (Pubitemid 35299886)
63. Choi JS, Nam K, Park JY, et al. Enhanced transfection efficiency of PAMAM dendrimer by surface modification with L-arginine. J Control Release 2004;94:445-456 (Pubitemid 39296913)
64. Kasai S, Nagasawa H, Shimamura M, et al. Design and synthesis of antiangiogenic/heparin-binding arginine dendrimer mimicking the surface of endostatin. Bioorg Med Chem Lett 2002;12:951-954 (Pubitemid 34214982)
65. Okuda T, Sugiyama A, Niidome T, Aoyagi H. Characters of dendritic poly(l-lysine) analogues with the terminal lysines replaced with arginines and histidines as gene carriers in vitro. Biomaterials 2004;25:537-544 (Pubitemid 37329706)
66. Nam HY, Hahn HJ, Nam K, et al. Evaluation of generations 2, 3 and 4 arginine modified PAMAM dendrimers for gene delivery. Int J Pharm 2008;363:199-205
67. Nam HY, Nam K, Hahn HJ, et al. Biodegradable PAMAM ester for enhanced transfection efficiency with low cytotoxicity. Biomaterials 2009;30:665-673
68. Kang H, De Long R, Fisher MH, Juliano RL. Tat-conjugated PAMAM dendrimers as delivery agents for antisense and siRNA oligonucleotides. Pharm Res 2005;22:2099-2106 (Pubitemid 41821589)
69. Luo D, Haverstick K, Belcheva N, et al. Poly(ethylene glycol)-conjugated PAMAM dendrimer for biocompatible, high-efficiency DNA delivery. Macromolecules 2002;35:3456-3462 (Pubitemid 34590324)
70. Lee JH, Lim YB, Choi JS, et al. Quaternized polyamidoamine dendrimers as novel gene delivery system: relationship between degree of quaternization and their influences. Bull Korean Chem Soc 2003;24:1637-1640
71. Vijayanathan V, Thomas T, Shirahata A, Thomas TJ. DNA condensation by polyamines: a laser scattering study of structural effects. Biochemistry 2001;40:13644-13651 (Pubitemid 33130792)
72. Bloomfield VA. DNA condensation by multivalent cations. Biopolymers 1997;44:269-282
73. Clamme JP, Bernacchi S, Vuilleumier C, et al. Gene transfer by cationic surfactants is essentially limited by the trapping of the surfactant/DNA complexes onto the cell membrane: a fluorescence investigation. Biochim Biophys Acta 2000;1467:347-361 (Pubitemid 30665588)
74. Remy JS, Sirlin C, Vierling P, Behr JP. Gene-transfer with a series of lipophilic DNA binding molecules. Bioconjugate Chem 1994;5:647-654
75. Schmiedl U, Ogan MD, Paajanen H, et al. Albumin labeled with Gd-DTPA as an intravascular, blood pool-enhancing agent for MR imaging: biodistribution and imaging studies. Radiology 1987;162:205-210 (Pubitemid 17001811)
76. Kobayashi H, Reijnders K, English S, et al. Application of a macromolecular contrast agent for detection of alterations of tumor vessel permeability induced by radiation. Clin Cancer Res 2004;10:7712-7720 (Pubitemid 39557536)
77. Myc A, Majoros IJ, Thomas TP, Baker JR Jr. Dendrimer-based targeted delivery of an apoptotic sensor in cancer cells. Biomacromolecules 2007;8:13-18 (Pubitemid 46140467)
78. Kim Y, Klutz AM, Hechler B, et al. Application of the functionalized congener approach to dendrimer-based signaling agents acting through A2A adenosine receptors. Purinergic Signal 2009;5(1):39-50
79. Alexander TY, Hisataka K, Sean JE, et al. Gadolinium-labeled dendrimers as biometric nanoprobes to detect vascular permeability. J Mater Chem 2003;13:1523-1525
80. Na M, Yiyun C, Tongwen X, et al. Dendrimers as potential drug carriers. Part II. Prolonged delivery of ketoprofen by in vitro and in vivo studies. Eur J Med Chem 2006;41:670-674
81. Kolhe P, Misra E, Kannan RM, et al. Drug complexation, in vitro release and cellular entry of dendrimers and hyperbranched polymers. Int J Pharm 2003;259:143-160 (Pubitemid 36638561)
82. Khandare J, Kolhe P, Pillai O, et al. Synthesis, cellular transport, and activity of polyamidoamine dendrimer-methylprednisolone conjugates. Bioconjug Chem 2005;16:330-337 (Pubitemid 40388208)
83. Wiwattanapatapee R, Lomlim L, Saramunee K. Dendrimers conjugates for colonic delivery of 5-aminosalicylic acid. J Control Release 2003;88:1-9 (Pubitemid 36173949)
84. Najlah M, Freeman S, Attwood D, D'Emanuele A. Synthesis, characterization and stability of dendrimer prodrugs. Int J Pharm 2006;308:175-182 (Pubitemid 43097250)
85. Chauhan AS, Jain NK, Diwan PV, Khopade AJ. Solubility enhancement of indomethacin with poly(amidoamine) dendrimers and targeting to inflammatory regions of arthritic rats. J Drug Target 2004;12:575-583
86. Gardiner J, Freeman S, Leach M, et al. PAMAM dendrimers for the delivery of the antibacterial Triclosan. J Enzyme Inhib Med Chem 2008;23:623-628
87. Cheng Y, Qu H, Ma M, et al. Polyamidoamine (PAMAM) dendrimers as biocompatible carriers of quinolone antimicrobials: an in vitro study. Eur J Med Chem 2007;42:1032-1038 (Pubitemid 46907335)
88. Kaminskas LM, Boyd BJ, Karellas P, et al. The impact of molecular weight and PEG chain length on the systemic pharmacokinetics of PEGylated poly-L-Lysine dendrimers. Mol Pharm 2008;5(3):449-463 (Pubitemid 351929829)
89. Chandrasekar D, Sistla R, Ahmad FJ, et al. The development of folate-PAMAM dendrimer conjugates for targeted delivery of anti-arthritic drugs and their pharmacokinetics and biodistribution in arthritic rats. Biomaterials 2007;28:504-512 (Pubitemid 44602223)
90. Jevprasesphant R, Penny J, Jalal R, et al. The influence of surface modification on the cytotoxicity of PAMAM dendrimers. Int J Pharm 2003;252:263-266 (Pubitemid 36126635)
91. Kolhatkar RB, Kitchens KM, Swaan PW, Ghandehari H. Surface acetylation of polyamidoamine (PAMAM) dendrimers decreases cytotoxicity while maintaining membrane permemability. Bioconjug chem 2007;18:2054-2060 (Pubitemid 350220008)
92. Yang H, Lopina ST, DiPersio LP, Schmidt SP. Stealth dendrimers for drug delivery: correlation between PEGylation, cytocompatibility, and drug payload. J Mater Sci Mater Med 2008;19:1991-1997
93. Van Vlerken LE, Vyas TK, Amiji MM. Poly(ethylene glycol)-modified nanocarriers for tumor-targeted and intracellular delivery. Pharm Res 2007;24:1405-1414 (Pubitemid 46988224)
94. Harris JM, Chess RB. Effect of PEGylation on pharmaceuticals. Nat Rev Drug Discov 2003;2:214-221
95. Greenwald RB, Conover CD, Choe YH. Poly(ethylene glycol) conjugated drugs and prodrugs: a comprehensive review. Crit Rev Ther Drug Carrier Syst 2000;17:101-161
96. Wood KC, Little SR, Langer R, Hammond PT. A family of hierarchically self-assembling linear-dendritic hybrid polymers for highly efficient targeted gene delivery. Angew Chem Int Ed Engl 2005;44:6704-6708 (Pubitemid 41532216)
97. Kojima C, Kono K, Maruyama K, Takagishi T. Synthesis of polyamidoamine dendrimers having poly(ethylene glycol) grafts and their ability to encapsulate anticancer drugs. Bioconjug Chem 2000;11:910-917
98. Kim Y, Klutz AM, Jacobson KA. Systematic investigation of polyamidoamine dendrimers surface-modified with poly(ethylene glycol) for drug delivery applications: synthesis, characterization, and evaluation of cytotoxicity. Bioconjug Chem 2008;19:1660-1672
99. Wang W, Xiong W, Wan J, et al. The decrease of PAMAM dendrimer - induced cytotoxicity by PEGylation via attenuation of oxidative stress. Nanotechnology 2009;20:1-7
100. Dung HT, Kim JS, Juliano RL, Yoo H. Preparation and evaluation of cholesteryl PAMAM dendrimers as nano delivery agents for antisense oligonucleotides. Colloids Surf A Physicochem Eng Aspects 2008;313-314:273-277 (Pubitemid 350299922)
101. Kim SH, Katenellenbogen JA. Hormone - PAMAM dendrimers conjugates: Polymer dynamics and tether structure affect ligand access to receptors. Angew Chem Int Ed 2006;45:7243-7248
102. Wiwattanapatapee R, Gomez BC, Malik N, Duncan R. Anionic PAMAM dendrimers rapidly cross adult rat intestine in vitro: a potential oral delivery system. Pharm Res 2000;17:2000
103. Santos JL, Oramas E, Pêgo AP, et al. Osteogenic differentiation of mesenchymal stem cells using PAMAM dendrimers as gene delivery vectors. J Control Release 2009;134(2):141-148
104. Choi YS, Cho TS, Kim JM, et al. Amine terminated G-6 PAMAM dendrimers and its interaction with DNA probed by Hoechst 33258. Biophys Chem 2006;121:142-149
105. Ackermann B, Engel BC, Buttlies B, Zibert A. Transgenic IL-2 expression in Ewing tumor cell lines after transfection with starburst dendrimers and cationic liposomes. Pediatr Hemtol Oncol 2002;19:509-520
106. Pawate S, Bhat NR. C-Jun N-terminal kinase (JNK) regulation of iNOS expression in glial cells: predominant role of JNK1 isoform. Antioxid Redox Signal 2006;8:903-909 (Pubitemid 44036507)
107. Zhang XQ, Wang XL, Huang RX, et al. In vitro gene delivery using polyamidoamine dendrimers with a trimesyl core. Biomacromolecules 2005;6:341-350
108. Patil ML, Zhang M, Betigeri S, et al. Surface-modified and internally cationic polyamidoamine dendrimers for efficient siRNA delivery. Bioconjug Chem 2008;19:1396-1403 (Pubitemid 352032339)
109. Maksimenko AV, Mandrouguine V, Gottikh MB, et al. Optimization of dendrimers - mediated gene transfer by anionic oligomers. J Gene Med 2003;5:61-71 (Pubitemid 40310368)
110. Bai S, Thomas C, Ahsan F. Dendrimers as a carrier for pulmonary delivery of Enoxaparin, a low-molecular weight heparin. J Pharm Sci 2007;96:2090-2106 (Pubitemid 47280103)
111. Devarakonda B, Hill RA, Liebenberg W, et al. Comparison of the aqueous solubilization of practically insoluble niclosamide by polyamidoamine (PAMAM) dendrimers and cyclodextrins. Int J Pharm 2005;304:193-209 (Pubitemid 41427662)
112. Ma M, Cheng Y, Xu Z, et al. Evaluation of polyamidoamine (PAMAM) dendrimers as drug carriers of anti-bacterial drugs using sulfamethoxazole (SMZ) as a model drug. Eur J Med Chem 2007;42:93-98 (Pubitemid 46198989)